

Table 1.123A Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 12 or Older; Numbers in Thousands, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	29,408	<i>27,026</i>	4,841	<i>4,779</i>	4,841	<i>4,779</i>
Benzodiazepine Tranquilizers	28,316	<i>26,095</i>	4,819	<i>4,739</i>	4,819	<i>4,739</i>
Alprazolam Products	16,748	<i>14,507</i>	3,668	<i>3,419</i>	3,668	<i>3,419</i>
Lorazepam Products	7,787	<i>7,189</i>	795	<i>723</i>	795	<i>723</i>
Clonazepam Products	5,998	<i>6,357</i>	1,029	<i>1,234</i>	1,029	<i>1,234</i>
Diazepam Products	5,672	<i>5,706</i>	758	<i>971</i>	758	<i>971</i>
Benzodiazepine Sedatives	1,729	<i>1,675</i>	68	<i>101</i>	68	<i>101</i>
Flurazepam	140	<i>113</i>	*	<i>16</i>	*	<i>*</i>
Temazepam Products	1,038	<i>898</i>	42	<i>83</i>	42	<i>*</i>
Triazolam Products	580	<i>689</i>	26	<i>27</i>	26	<i>*</i>
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>58</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.123B Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 12 or Older; Percentages, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	10.7	<i>9.8</i>	1.8	<i>1.7</i>	16.5	<i>17.7</i>
Benzodiazepine Tranquilizers	10.3	<i>9.4</i>	1.8	<i>1.7</i>	17.0	<i>18.2</i>
Alprazolam Products	6.1	<i>5.2</i>	1.3	<i>1.2</i>	21.9	<i>23.6</i>
Lorazepam Products	2.8	<i>2.6</i>	0.3	<i>0.3</i>	10.2	<i>10.1</i>
Clonazepam Products	2.2	<i>2.3</i>	0.4	<i>0.4</i>	17.2	<i>19.4</i>
Diazepam Products	2.1	<i>2.1</i>	0.3	<i>0.4</i>	13.4	<i>17.0</i>
Benzodiazepine Sedatives	0.6	<i>0.6</i>	0.0	<i>0.0</i>	3.9	<i>6.0</i>
Flurazepam	0.1	<i>0.0</i>	*	<i>0.0</i>	*	*
Temazepam Products	0.4	<i>0.3</i>	0.0	<i>0.0</i>	4.1	*
Triazolam Products	0.2	<i>0.2</i>	0.0	<i>0.0</i>	4.4	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>0.0</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.124A Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 12 to 17; Numbers in Thousands, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	749	<i>418</i>	381	<i>157</i>	381	*
Benzodiazepine Tranquilizers	700	<i>398</i>	371	<i>152</i>	371	*
Alprazolam Products	613	<i>308</i>	359	<i>151</i>	359	*
Lorazepam Products	84	<i>48</i>	9	<i>9</i>	*	*
Clonazepam Products	83	<i>41</i>	33	<i>2</i>	*	*
Diazepam Products	80	<i>44</i>	16	<i>7</i>	*	*
Benzodiazepine Sedatives	69	<i>25</i>	11	<i>5</i>	*	*
Flurazepam	10	<i>9</i>	3	<i>5</i>	*	*
Temazepam Products	23	*	2	*	*	*
Triazolam Products	39	<i>16</i>	6	*	*	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	*	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.124B Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 12 to 17; Percentages, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	3.0	<i>1.7</i>	1.5	<i>0.6</i>	50.9	*
Benzodiazepine Tranquilizers	2.8	<i>1.6</i>	1.5	<i>0.6</i>	52.9	*
Alprazolam Products	2.5	<i>1.2</i>	1.4	<i>0.6</i>	58.6	*
Lorazepam Products	0.3	<i>0.2</i>	0.0	<i>0.0</i>	*	*
Clonazepam Products	0.3	<i>0.2</i>	0.1	<i>0.0</i>	*	*
Diazepam Products	0.3	<i>0.2</i>	0.1	<i>0.0</i>	*	*
Benzodiazepine Sedatives	0.3	<i>0.1</i>	0.0	<i>0.0</i>	*	*
Flurazepam	0.0	<i>0.0</i>	0.0	<i>0.0</i>	*	*
Temazepam Products	0.1	*	0.0	*	*	*
Triazolam Products	0.2	<i>0.1</i>	0.0	*	*	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	*	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.125A Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 18 or Older; Numbers in Thousands, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	28,659	<i>26,607</i>	4,460	<i>4,622</i>	4,460	<i>4,622</i>
Benzodiazepine Tranquilizers	27,615	<i>25,697</i>	4,448	<i>4,587</i>	4,448	<i>4,587</i>
Alprazolam Products	16,134	<i>14,199</i>	3,308	<i>3,269</i>	3,308	<i>3,269</i>
Lorazepam Products	7,703	<i>7,140</i>	786	<i>714</i>	786	<i>714</i>
Clonazepam Products	5,916	<i>6,316</i>	996	<i>1,232</i>	996	<i>1,232</i>
Diazepam Products	5,592	<i>5,662</i>	742	<i>965</i>	742	<i>965</i>
Benzodiazepine Sedatives	1,660	<i>1,650</i>	57	<i>96</i>	57	<i>96</i>
Flurazepam	130	<i>104</i>	*	*	*	*
Temazepam Products	1,015	<i>898</i>	41	<i>83</i>	41	*
Triazolam Products	541	<i>673</i>	19	<i>27</i>	19	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>58</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.125B Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 18 or Older; Percentages, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	11.4	<i>10.6</i>	1.8	<i>1.8</i>	15.6	<i>17.4</i>
Benzodiazepine Tranquilizers	11.0	<i>10.2</i>	1.8	<i>1.8</i>	16.1	<i>17.9</i>
Alprazolam Products	6.4	<i>5.6</i>	1.3	<i>1.3</i>	20.5	<i>23.0</i>
Lorazepam Products	3.1	<i>2.8</i>	0.3	<i>0.3</i>	10.2	<i>10.0</i>
Clonazepam Products	2.4	<i>2.5</i>	0.4	<i>0.5</i>	16.8	<i>19.5</i>
Diazepam Products	2.2	<i>2.2</i>	0.3	<i>0.4</i>	13.3	<i>17.0</i>
Benzodiazepine Sedatives	0.7	<i>0.7</i>	0.0	<i>0.0</i>	3.4	<i>5.8</i>
Flurazepam	0.1	<i>0.0</i>	*	*	*	*
Temazepam Products	0.4	<i>0.4</i>	0.0	<i>0.0</i>	4.0	*
Triazolam Products	0.2	<i>0.3</i>	0.0	<i>0.0</i>	3.6	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>0.0</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.126A Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 18 to 25; Numbers in Thousands, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	2,983	<i>2,861</i>	1,266	<i>1,097</i>	1,266	<i>1,097</i>
Benzodiazepine Tranquilizers	2,922	<i>2,822</i>	1,260	<i>1,087</i>	1,260	<i>1,087</i>
Alprazolam Products	2,229	<i>1,992</i>	1,091	<i>932</i>	1,091	<i>932</i>
Lorazepam Products	630	<i>701</i>	132	<i>169</i>	132	<i>169</i>
Clonazepam Products	599	<i>641</i>	214	<i>216</i>	214	*
Diazepam Products	451	<i>561</i>	138	<i>117</i>	138	*
Benzodiazepine Sedatives	113	<i>146</i>	28	<i>16</i>	*	*
Flurazepam	12	<i>16</i>	3	*	*	*
Temazepam Products	38	<i>22</i>	20	<i>9</i>	*	*
Triazolam Products	75	<i>108</i>	12	<i>7</i>	*	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>4</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.126B Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 18 to 25; Percentages, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	8.8	8.5	3.8	3.3	42.4	38.3
Benzodiazepine Tranquilizers	8.7	8.4	3.7	3.2	43.1	38.5
Alprazolam Products	6.6	5.9	3.2	2.8	49.0	46.8
Lorazepam Products	1.9	2.1	0.4	0.5	21.0	24.1
Clonazepam Products	1.8	1.9	0.6	0.6	35.7	*
Diazepam Products	1.3	1.7	0.4	0.4	30.6	*
Benzodiazepine Sedatives	0.3	0.4	0.1	0.0	*	*
Flurazepam	0.0	0.0	0.0	*	*	*
Temazepam Products	0.1	0.1	0.1	0.0	*	*
Triazolam Products	0.2	0.3	0.0	0.0	*	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	da	*	0.0	da	da

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.127A Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 26 or Older; Numbers in Thousands, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	25,676	<i>23,747</i>	3,194	<i>3,526</i>	3,194	<i>3,526</i>
Benzodiazepine Tranquilizers	24,693	<i>22,875</i>	3,188	<i>3,500</i>	3,188	<i>3,500</i>
Alprazolam Products	13,906	<i>12,207</i>	2,217	<i>2,336</i>	2,217	<i>2,336</i>
Lorazepam Products	7,074	<i>6,439</i>	654	<i>545</i>	654	<i>545</i>
Clonazepam Products	5,317	<i>5,675</i>	782	<i>1,016</i>	782	<i>1,016</i>
Diazepam Products	5,141	<i>5,101</i>	604	<i>847</i>	604	<i>847</i>
Benzodiazepine Sedatives	1,547	<i>1,503</i>	29	<i>80</i>	29	<i>80</i>
Flurazepam	118	<i>88</i>	*	<i>12</i>	*	<i>*</i>
Temazepam Products	977	<i>875</i>	21	<i>74</i>	21	<i>*</i>
Triazolam Products	466	<i>565</i>	*	<i>20</i>	*	<i>*</i>
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>54</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.127B Any Use and Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Benzodiazepine Subtypes in Past Year: Among Past Year Any Users of Prescription Benzodiazepine Subtypes Aged 26 or Older; Percentages, 2019 and 2020

Benzodiazepine Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Benzodiazepine Subtypes (2020)
ANY PRESCRIPTION BENZODIAZEPINE	11.9	<i>10.9</i>	1.5	<i>1.6</i>	12.4	<i>14.8</i>
Benzodiazepine Tranquilizers	11.4	<i>10.5</i>	1.5	<i>1.6</i>	12.9	<i>15.3</i>
Alprazolam Products	6.4	<i>5.6</i>	1.0	<i>1.1</i>	15.9	<i>19.1</i>
Lorazepam Products	3.3	<i>2.9</i>	0.3	<i>0.2</i>	9.2	<i>8.5</i>
Clonazepam Products	2.5	<i>2.6</i>	0.4	<i>0.5</i>	14.7	<i>17.9</i>
Diazepam Products	2.4	<i>2.3</i>	0.3	<i>0.4</i>	11.7	<i>16.6</i>
Benzodiazepine Sedatives	0.7	<i>0.7</i>	0.0	<i>0.0</i>	1.9	<i>5.3</i>
Flurazepam	0.1	<i>0.0</i>	*	<i>0.0</i>	*	*
Temazepam Products	0.5	<i>0.4</i>	0.0	<i>0.0</i>	2.2	*
Triazolam Products	0.2	<i>0.3</i>	*	<i>0.0</i>	*	*
Any Miscellaneous Prescription Benzodiazepine Tranquilizers or Sedatives ¹	da	<i>da</i>	*	<i>0.0</i>	da	<i>da</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes misuse of benzodiazepine tranquilizers that were specified as other sedatives and benzodiazepine sedatives that were specified as other tranquilizers.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.